Tripti Khare

TL;DR: The focus in this review is to summarize the use of phytochemicals and macromolecules encapsulated in nanoparticles for the treatment of IBD and IBD-associated colorectal cancer.

TL;DR: A review of the current knowledge of chemokine CXCL12 and its receptors CXCR4 and CX CR7 is presented in this paper, with an emphasis on targeting the C-X-C motif chemokINE 12-CX-CR4/CXCR7 axis as a treatment strategy for CRC.

TL;DR: Micro/nano formulations developed using biomacromolecules like chitosan, zein, pectin, casein, alginate, dextran, glucomannan and hyaluronic acid have been reviewed focusing on their potential in protecting active cargo, avoiding premature release, distal colon targeting along with their impact on reshaping the altered gut microbiota and how it can ameliorate the colitis conditions.

TL;DR: Current status of the implication of epigenetic therapy in CRC is discussed and Interestingly, DNA methyltransferase inhibitors and histone deacetylase inhibitors have shown promising results in controlling cancer progression.

TL;DR: DNA methylation and 5-hydroxymethylcytosine aberrations were investigated to better understand the epigenetic regulation of C-X-C motif chemokine receptor 4 in colorectal cancer (CRC).